Verzenio (abemaciclib) / Eli Lilly, Innovent Biologics - LARVOL DELTA

Overall survival from the Phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

BUB1 and CDK4/6 Dual Inhibition Increases Radiation Sensitivity in Glioblastoma, Lung Cancer, and Triple-Negative Breast Cancer. (PubMed, Biomedicines) - " GBM, LC, and TNBC cell lines were treated with BUB1 inhibitor BAY1816032, CDK4/6 inhibitors ribociclib and abemaciclib, and radiation. Persistent RPA32 Ser33 phosphorylation reflects ATR-dependent resection that requires BLM and EXO1 at later stages, supporting sustained resection and unresolved repair leading to increased cell death. Dual inhibition of BUB1 and CDK4/6 represents a promising therapeutic strategy for enhancing radiosensitivity in GBM, lung cancer, and TNBC, particularly in Rb-intact settings."

Journal • Brain Cancer • Breast Cancer • Glioblastoma • Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BUB1 • HRD • RAD51 • RPA2

Pneumonitis Associated with Immune Checkpoint Inhibitors and Targeted Anticancer Therapies: A Retrospective Case Series of 12 Patients. (PubMed, Diseases) - "Immunotherapy- and targeted therapy-induced pneumonitis can express various features and severities, and prompt recognition and diagnosis based on clinical, radiologic and contextual elements are mandatory. In this small, heterogeneous series the individualized corticosteroid regimens used were followed by favorable outcomes. Our observations suggest that, in selected clinically improving patients, follow-up may rely only on clinical assessment and chest X-ray, and extensive tests may be reserved for non-responsive cases."

Checkpoint inhibition • Journal • Retrospective data • Breast Cancer • Hematological Malignancies • Inflammation • Kidney Cancer • Lung Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Pulmonary Disease • Renal Cell Carcinoma • Respiratory Diseases • Solid Tumor

Phase I/II Study of Concurrent Abemaciclib and Adjuvant Radiotherapy in Patients with HR+, HER2-, High-Risk Breast Cancer (ASTRO 2026) - P=N/A | "The 150 mg twice-daily dose of abemaciclib demonstrated a favorable safety profile during phase I dose escalation. The observed adverse events were consistent with those expected from abemaciclib or radiotherapy alone. Although grade 3 leukopenia and neutropenia were common, these events were manageable, reversible."

Clinical • P1/2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

ctDNA Evaluation on a Phase I Trial of Pre-Operative Ablative Radiation for Early Stage Hormone Positive Breast Cancer (ASTRO 2026) - P1 | "She received adjuvant Taxol , Xeloda and whole breast/nodal radiation. ctDNA rose again 9 months post-surgery, declined while on Verzenio then became (+, 0.10) again roughly 2 years after sPBI despite negative PET imaging... This exploratory analysis shows a low rate of detectable ctDNA in early stage (cT1-T2N0) breast cancer, with ctDNA identified in 3/12 patients (25%). Most detections occurred in patients who were ultimately found to have higher stage disease, suggesting that ctDNA(+) may indicate occult nodal involvement. Among true stage I-II patients baseline ctDNA detection was rare (1/12, 8.3%) limiting its usefulness for routine monitoring."

Circulating tumor DNA • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Three-month persistence and adherence to adjuvant abemaciclib in high-risk HR+, HER2− early breast cancer: real world data from ABSIDE-S (ESMO 2026) - No abstract available

Adherence • Clinical • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Early Toxicity–Driven Dose Modification Preserves Efficacy of Adjuvant Abemaciclib in High-Risk HR+/HER2− Early Breast Cancer: A Real-World Study in Chinese Patients (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Phase I/II Study of Concurrent Abemaciclib and Adjuvant Radiotherapy in Patients with HR+, HER2-, High-Risk Breast Cancer (ASTRO 2026) - P=N/A | "The 150 mg twice-daily dose of abemaciclib demonstrated a favorable safety profile during phase I dose escalation. The observed adverse events were consistent with those expected from abemaciclib or radiotherapy alone. Although grade 3 leukopenia and neutropenia were common, these events were manageable, reversible."

Clinical • P1/2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Outcomes and Toxicity of Concurrent CDK46 Inhibitor and Adjuvant Radiation Therapy in Early Breast Cancer (ASTRO 2026) - "Abemaciclib and radiotherapy appears to be better tolerated than ribociclib or dalpiciclib combined with radiotherapy. Although high grade hematologic toxicities were often observed, but most patients treated with abemaciclib did not modify their treatment during radiotherapy."

Clinical • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

ctDNA Evaluation on a Phase I Trial of Pre-Operative Ablative Radiation for Early Stage Hormone Positive Breast Cancer (ASTRO 2026) - P1 | "She received adjuvant Taxol , Xeloda and whole breast/nodal radiation. ctDNA rose again 9 months post-surgery, declined while on Verzenio then became (+, 0.10) again roughly 2 years after sPBI despite negative PET imaging... This exploratory analysis shows a low rate of detectable ctDNA in early stage (cT1-T2N0) breast cancer, with ctDNA identified in 3/12 patients (25%). Most detections occurred in patients who were ultimately found to have higher stage disease, suggesting that ctDNA(+) may indicate occult nodal involvement. Among true stage I-II patients baseline ctDNA detection was rare (1/12, 8.3%) limiting its usefulness for routine monitoring."

Circulating tumor DNA • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Toxicity, Dose Reductions and Clinical Predictors in HR+/HER2- Early Breast Cancer Patients Treated with Abemaciclib in Adjuvant Setting: a Real-world Analysis (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Real-world tolerability and treatment exposure with adjuvant abemaciclib in high-risk HR+, HER2- early breast cancer (EBC) (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Real-World 2-Year IDFS and Post-Progression Outcomes Following Adjuvant Abemaciclib (AA): Updated CONCISE-UK Analysis (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Oncology

First Real-World Retrospective Assessment of Adjuvant Abemaciclib in Early HR+/HER2– Breast Cancer in Costa Rica: Hospital México Cohort and Initial Evidence for the Central American Region (ESMO 2026) - No abstract available

Real-world • Real-world evidence • Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Dosing strategies and tolerability of adjuvant abemaciclib in HR+/HER2− early breast cancer: a single-center real-world analysis (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Treatment Persistence and Clinical Characteristics in Patients with HR+, HER2-, High-Risk Early Breast Cancer (EBC) Treated with Abemaciclib: A Multi-Country Real-World Study (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Early Toxicity Dynamics and Treatment Persistence with Adjuvant Abemaciclib: A Real-World Study Including Elderly Patients (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Oncology

Dose reductions and adverse events related discontinuations of adjuvant abemaciclib in high-risk HR+/HER2− breast cancer: a multicenter real-world experience (ESEA study) (ESMO 2026) - No abstract available

Adverse events • Clinical • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Machine learning identifies a low-risk subgroup within clinically high-risk ER-positive/HER2-negative early breast cancer eligible for adjuvant abemaciclib (ESMO 2026) - No abstract available

Clinical • Machine learning • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Co-Inhibition of BUB1 and CDK4/6 Augments Radiation Response in TNBC, Glioblastoma, and Lung Cancer (ASTRO 2026) - "Materials/ Cell proliferation, clonogenic survival, and immunoblot analyses were conducted in GBM, TNBC, and LC cell lines treated with the BUB1 inhibitor BAY1816032, CDK4/6 inhibitors (ribociclib, abemaciclib), and radiation. Dual inhibition of BUB1 and CDK4/6 represents a promising therapeutic strategy for enhancing radiosensitivity and overcoming intrinsic or acquired resistance in aggressive solid tumors. These results support the development of combination approaches targeting complementary G1/S and G2/M cell-cycle nodes to improve radiotherapy efficacy and limit tumor adaptation."

Brain Cancer • Glioblastoma • Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BUB1 • CDK4 • RAD51

Association of p27 V109G SNP zygosity with outcomes and abemaciclib treatment effect in HR+, HER2− high-risk early breast cancer: results from monarchE (ESMO 2026) - No abstract available

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Abemaciclib in Patients With Oligodendroglioma (clinicaltrials.gov) - P2 | N=10 | Completed | Sponsor: Stephen Bagley, MD, MSCE | Active, not recruiting ➔ Completed | Trial completion date: May 2027 ➔ Feb 2026

Trial completion • Trial completion date • Brain Cancer • Glioma • Oligodendroglioma • Oncology • Solid Tumor

Relapse during or soon after adjuvant abemaciclib in high-risk HR+/HER2- early breast cancer: Early AB-ITALY (ESMO 2026) - No abstract available

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Drug-PIN risk classification and treatment-related toxicity in patients receiving abemaciclib for early or metastatic breast cancer (ESMO 2026) - No abstract available

Clinical • Metastases • Breast Cancer • Oncology • Solid Tumor

Validation of the Systemic Treatment-Induced Diarrhea Assessment Tool (STIDAT) in patients with early breast cancer treated with abemaciclib in a randomized study (ESMO 2026) - No abstract available

Clinical • Breast Cancer • Oncology • Solid Tumor